Testing BCG treatment for bladder cancer after full tumor removal
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your bladder cancer is non-muscle invasive (stage Ta or T1) and has been completely removed by surgery, with confirmed pathology within 45 days.
- Your cancer is intermediate- or high-risk, and it was diagnosed within 45 days of joining the study.
- If your cancer is T1: scans (CT or MRI) show no spread to distant areas, and you must have had a repeat bladder surgery (repeat TURBT) with results reviewed within the required time window.
- You can do study activities and are able to take part (ECOG 0–2) and your blood/organ tests are high enough.
- You have not previously had bladder BCG treatments or certain other bladder cancer types, and you are not currently getting other cancer therapies during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
This study looks at whether the bladder is ready to receive BCG, a medicine placed directly into the bladder, after surgeons remove a new bladder lesion. It may help doctors understand the best timing and preparation for BCG in early (non-muscle-invasive) bladder cancer.
This trial tests whether radiation therapy can help people whose bladder cancer (specifically carcinoma in situ) did not get better with BCG treatment and who are not having their bladder removed. It aims to offer a less invasive option for controlling the cancer.
This study is testing whether a urine or blood test can help guide BCG treatment for high-risk bladder cancer that hasn't spread into the muscle. It is only for people over 65 who are new to BCG therapy.
This study tries to predict whether BCG treatment will work for people with certain early-stage bladder cancers. It may help doctors better choose and monitor BCG for similar patients in the future.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.